Amgen to participate in Oncologic Drugs Advisory Committee in May

Drugs :: Amgen to participate in Oncologic Drugs Advisory Committee in May

Amgen (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has invited the Company to participate at an upcoming meeting of the Oncologic Drugs Advisory Committee (ODAC).

The Company?s understanding is that the ODAC will review progress made by Amgen and other sponsors in delineating the effects of erythropoiesis-stimulating agents (ESAs) on survival and tumor progression in cancer patients. The ODAC meeting is scheduled for May 10, 2007.

?We look forward to providing an update to the ODAC on the Aranesp? (darbepoetin alfa) 103 trial involving cancer patients with anemia not due to chemotherapy. We have recently posted a detailed synopsis of the study results on public Web sites, including clinicalstudyresults.org and clinicaltrials.gov,? said Roger M. Perlmutter, M.D., Ph.D., executive vice president of research and development for Amgen.

?The upcoming ODAC meeting will also provide a forum for the review of our ongoing Aranesp pharmacovigilance program,? Dr. Perlmutter continued, ?which we undertook following the May 2004 ODAC meeting, including a review of data then available from the Aranesp 145 trial involving patients with previously untreated small cell lung cancer.? Dr. Perlmutter noted that the Aranesp 145 trial has reached its pre-specified number of events. Amgen is now collecting data from the trial and expects to announce topline results from this study in May.

Additionally, Amgen is in discussions with the FDA with the goal of updating patient safety information on all ESA labels that will take the form of a boxed warning and will apply to both nephrology and oncology indications for the class of approved ESAs. While Amgen?s interactions with the FDA are ongoing and exact language for the updated prescribing information is not final, the company is committed to providing timely and appropriate communications to patients and physicians. When the updated prescribing information is final, Amgen will inform healthcare professionals about the revisions to the U.S. prescribing information through a ?Dear Healthcare Professional? letter and will post the letter and updated prescribing information on Amgen?s web site, www.amgen.com.

Amgen?s top priority is patient safety. Aranesp is indicated for the treatment of chemotherapy-induced anemia and anemia associated with chronic kidney disease (CKD), for patients on dialysis and patients not on dialysis. EPOGEN? (Epoetin alfa) is indicated for the treatment of anemia associated with CKD, for patients on dialysis. The dosing instructions recommend targeting hemoglobin levels not to exceed 12 g/dL. Amgen always recommends that physicians and other prescribers carefully follow FDA-approved prescribing instructions.


(Drugs :: Amgen to participate in Oncologic Drugs Advisory Committee in May published at SpiritIndia on Thursday, March 1, 2007)

Drugs

Search more information on Drugs, Drugs books

Recently posted related articles on Drugs :

1. Lupus :: Existing drugs show promise for treating end-stage renal disease in lupus
2. Drug :: Computational modeling could improve antibody drugs
3. Alzheimer's Disease :: Cautious optimism for new drugs for Alzheimer's disease
4. Tuberculosis :: New MDR TB drugs to hit market in 4-5 years
5. Depression :: Anti-depressant drugs can double risk of gastrointestinal bleeding
6. Drug :: APhA applauds FDA's decision about Behind the Counter class of drugs
7. Drug :: US Law strengthens FDA to regulate food, drugs, and medical devices in a better way
8. Thyroid :: FDA acts to ensure thyroid drugs don't lose potency before expiration date
9. Leishmaniasis :: New system to lead to safer drugs for tropical disease leishmaniasis
10. Cancer :: Researchers studying model to learn why certain cancers become resistant to drugs

Most related articles:

- Drugs :: Amgen to participate in Oncologic Drugs Advisory Committee in May
- Osteosarcoma :: FDA reviews IDM Pharma's Junovan for treatment of osteosarcoma - 14.3
- Avandia :: Keep GSK diabetes drug Avandia available to US patients - 10.4
- Avandia :: FDA Advisory Panel supports Glaxo's diabetes drug Avandia - 9.8
- Anemia :: FDA strengthens safety information for anemia drugs - 9.4
- FDA :: FDA proposes tougher procedures for membership on advisory committees - 9.2
- Breast Cancer :: FDA recommends Evista use to reduce breast cancer risk in postmenopausal women - 9
- FDA :: FDA Announces New Advisory Committee to Address Risk Communication - 8.9
- Influenza :: FDA Advisory Committee Recommends Expanded Use of FluMist - 7.8
- Leukemia :: Clolar approved for childhood leukemia - 7.2

Drugs - recent related articles/news stories:

- TNF blockers will have boxed warning cancer risk
- Artemisinin based anti malarial drugs becoming resistant to malaria
- India to control spurious drugs
- Boxed warning required for Chantix and Zyban, says FDA
- Bone density unnecessary in women taking osteoporosis drugs

»»   FDA :: Avanir Pharmaceuticals summarizes outcome of FDA meeting on Zenvia NDA
««   Growth Hormone :: Use of growth hormone to boost athletic performance can lead to diabetes

Home | Cancer | Therapies | Diet | Herbs | Heart | Skin | Cosmetic Surgery | Arthritis | Allergies | Eyes | GIT | Glossary | List

AYUSH = Ayurveda - Yoga - Unani - Siddha - Homeopathy -- Health articles

The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com